Close
  • About Us
  • Careers
  • Downloads
  • Refer & Earn
  • Contact Us
  • SMC open account icon Open an A/C
    • Open an A/C
    • CHOOSE YOUR OPTION(S)
    • Trading A/c
    • Mutual Fund A/c
    • NBFC A/c
    • NPS A/c
  • SENSEX Mar 31 2023 12:00
    58,991.52 +1,031.43 ( +1.78%)
  • NIFTY Mar 31 2023 12:00
    17,359.75 +279.05 ( +1.63%)
  • SENSEX Mar 31 2023 12:00
    58,991.52 +1,031.43 ( +1.78%)
  • NIFTY Mar 31 2023 12:00
    17,359.75 +279.05 ( +1.63%)
  • Nasdaq Apr 01 2023 04:30
    12,221.91 +208.44 ( +1.74%)
  • DJIA Apr 01 2023 04:30
    33,274.15 +415.12 ( +1.26%)
  • S&P 500 Apr 01 2023 04:30
    4,109.31 +58.48 ( +1.44%)
  • Hang Seng Mar 31 2023 02:10
    20,400.11 +90.98 ( +0.45%)
  • Crude Oil Mar 31 2023 11:30
    6,195.00 +102.00 ( +1.67%)
  • Gold Mar 31 2023 11:27
    59,371.00 +55.00 ( +0.09%)
  • Silver Mar 31 2023 11:29
    72,205.00 +431.00 ( +0.60%)
  • Copper Mar 31 2023 11:29
    779.30 -0.25 (-0.03%)
  • Pound / Rupee Dec 23 2016 22:30
    101.37 +0.06 ( +0.06%)
  • Dollar / Rupee Dec 23 2016 22:30
    82.26 +0.04 ( +0.04%)
  • Euro / Rupee Dec 23 2016 22:30
    89.18 +0.15 ( +0.17%)
  • Yen / Rupee Dec 23 2016 22:30
    0.62 -0.01 (-0.95%)

Divis Laboratories Ltd

BSE Code : 532488 | NSE Symbol : DIVISLAB | ISIN:INE361B01024| SECTOR : Pharmaceuticals |

NSE BSE
 
SMC up arrow

2,823.35

3.10 (0.11%) Volume 362732

31-Mar-2023 EOD

Prev. Close

2,820.25

Open Price

2,834.40

Bid Price (QTY)

2,823.35(124)

Offer Price (QTY)

0.00(0)

 

Today’s High/Low 2,840.25 - 2,810.80

52 wk High/Low 4,640.80 - 2,730.00

Key Stats

MARKET CAP (RS CR) 75014.78
P/E 31.62
BOOK VALUE (RS) 454.8453047
DIV (%) 1500
MARKET LOT 1
EPS (TTM) 89.36
PRICE/BOOK 6.21255176386566
DIV YIELD.(%) 1.06
FACE VALUE (RS) 2
DELIVERABLES (%) 57.67
4

News & Announcements

13-Mar-2023

Divis Laboratories Ltd - Divis Laboratories Limited - Analysts/Institutional Investor Meet/Con. Call Updates

11-Mar-2023

Divis Laboratories Ltd - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

10-Mar-2023

Divis Laboratories Ltd down for fifth straight session

08-Feb-2023

Divis Laboratories Ltd - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011

24-Jan-2023

Divis Laboratories to conduct board meeting

28-Oct-2022

Divis Laboratories to announce Quarterly Result

29-Jul-2022

Divis Laboratories schedules board meeting

05-Jul-2022

Divis Laboratories to convene AGM

Corporate Actions

Bonus
Splits
Dividends
Rights
Capital Structure
Book Closure
Board Meeting
AGM
EGM
 

Financials

Income Statement

Standalone
Consolidated
 

Peers Comparsion

Select Company Name BSE Code NSE Symbol
Aarey Drugs & Pharmaceuticals Ltd 524412 AAREYDRUGS
Aarti Drugs Ltd 524348 AARTIDRUGS
Add Life Pharma Ltd 524665
Adithya Alkaloids Pvt Ltd 524320
Alpha Drug India Ltd(merged) 500006 ALPHADRUG
Ami Organics Ltd 543349 AMIORG
Anuh Pharma Ltd 506260
Anus Laboratories Ltd 532981
Arch Pharmalabs Ltd 524729
Aster Drugs & Pharmaceuticals Ltd 40286
Auro Laboratories Ltd 530233
Auromed Ltd 532103
Bacil Pharma Ltd 524516
Beta Drugs Ltd 535022 BETA
Betalact Laboratories Ltd 531238
Biotech Synergy Ltd 40183
Cheminor Drugs Ltd (Merged) 524140 CHEMNODRUG
Chemo Pharma Laboratories Ltd 506365
Chemox Chemical Industries Ltd (Wound-up) 512042 CHEMOXCHEM
Chiplun Fine Chemicals Ltd 530417
Core Laboratories Ltd (Merged) 506963
Coromandel Pharmaceuticals Ltd 524524
Daurala Organics Ltd(merged) 524256 DAURALAORG
Denis Chem Lab Ltd 537536
Dishman Pharmaceuticals and Chemicals Ltd(Merged) 532526 DISHMAN
Dynachem Pharmaceuticals (Export) Ltd 524562 DYNAPHARMA
Elder Pharmaceuticals Ltd 532322 ELDERPHARM
Elegant Pharmaceuticals Ltd 524344
Emergy Phaarma Ltd 524812
Everest Organics Ltd 524790
Fermenta Biotech Ltd 506414
Fernhill Industries Ltd 531466
Fine Drugs And Chemicals Ltd (Merged) 524782
Gennex Laboratories Ltd 531739
Gennex Laboratories Ltd Partly Paidup 890171
Gland Pharma Ltd 543245 GLAND
Godavari Drugs Ltd 530317
Granules India Ltd 532482 GRANULES
Gujarat Lyka Organics Ltd (Merged) 506930
Gujarat Themis Biosyn Ltd 506879 GUJTHEMIS
Hallmark Drugs & Chemicals Ltd 531407
Harshita Ltd 531347
Hikal Ltd 524735 HIKAL
Hiran Orgochem Ltd 506170
Hi-Tech Drugs Ltd 524424
Ishita Drugs & Industries Ltd 524400
J K Pharmachem Ltd 500218 JKPHARMA
Janak Intermediates Ltd 524380
Jubilant Pharmova Ltd 530019 JUBLPHARMA
Kaprinas Pharmaceuticals & Chemicals Ltd 530147
Kimia Biosciences Ltd 530313
Konar Organics Ltd 526933
Krebs Biochemicals & Industries Ltd 524518 KREBSBIO
Kwality Pharmaceuticals Ltd 539997
Lactose (India) Ltd 524202
Larite Industries Ltd 512325
Lupin Ltd 500257 LUPIN
Magnum Intermediates Ltd 40177
Manav Pharma Ltd 524390
Marksans Pharma Ltd 524404 MARKSANS
Medicorp Technologies India Ltd (Merged) 532108 MEDICOTECH
Nagarjuna Drugs Ltd 530064
Nagarjuna Nature Base Ltd 40353
Nalin Chemicals Ltd 531292
Natco Laboratories Ltd (Merged) 500299 NATCOLABS
Nectar Lifescience Ltd 532649 NECLIFE
Neuland Laboratories Ltd 524558 NEULANDLAB
NGL Fine Chem Ltd 524774 NGLFINE
Nutraplus India Ltd 524764
Orchid Pharma Ltd 524372 ORCHPHARMA
Oxygenta Pharmaceutical Ltd 524636
Paam Drugs & Pharmaceuticals Ltd 524462 PAAMDRUG
Pan India Drugs & Chemicals Ltd 524560
Panchsheel Organics Ltd 531726 PANCHSHEEL
Par Drugs & Chemicals Ltd 535341 PAR
Parabolic Drugs Ltd 533211 PARABDRUGS
Parmax Pharma Ltd 540359
Pharmed Chemicals Ltd 524733
Piramal Phytocare Ltd(Merged) 532979 PIRPHYTO
Plama Laboratories Ltd (Merged) 524798
Pradeep Drug Company Ltd (Merged) 524246
Ratna Drugs Ltd 524382
Regent Chemicals Ltd 506989
Richline Pharma Ltd 524460
Roopa Industries Ltd 530991
Rupal Chemical Industries Ltd (Merged) 524705
Rupangi Impex Ltd (Wound-up) 512606 RUPANGIMPX
Samrat Pharmachem Ltd 530125
Sequent Scientific Ltd 512529 SEQUENT
Sharvani Pharmaceuticals Ltd 40159
Shasun Pharmaceuticals Ltd(Merged) 524552 SHASUNPHAR
Shilpa Medicare Ltd 530549 SHILPAMED
Shilpax Laboratories Ltd 524482
Shrishma Fine Chemicals (Karnataka) Ltd 507000
Siris Ltd 524746 SIRIS
Smruthi Organics Ltd 540686
SMS Pharmaceuticals Ltd 532815 SMSPHARMA
Southern Herbals Ltd 500395 SOUTHNHERB
Sri Chakra Remedies Ltd (Merged) 507484
Stellar Drugs Ltd 524612
Sterling Basic Organics Ltd 524644
Suven Life Sciences Ltd 530239 SUVEN
Swet-Chem Antibiotics Ltd 531186
Targof Pure Drugs Ltd 40230
Teem Laboratories Ltd 507761
Transchem Ltd 500422 TRANSCHEM
Umedix India Ltd 524822
Venkat Pharma Ltd 532093
Venmax Drugs & Pharmaceuticals Ltd 531015
Vera Laboratories Ltd (Merged) 40228
Vitara Chemicals Ltd 524646 VITARACHEM
Vivo Bio Tech Ltd 511509
Vorin Laboratories Ltd (Merged) 524508
Wanbury Ltd 524212 WANBURY
Zora Pharma Ltd(merged) 524438
Zyden Gentec Ltd 530091

Share Holding

Category No. of shares Percentage
Total Foreign 41971025 15.81
Total Institutions 54875958 20.67
Total Govt Holding 135 0.00
Total Non Promoter Corporate Holding 3745142 1.41
Total Promoters 137886200 51.94
Total Public & others 26990120 10.18
Total 265468580 100
  • Total Foreign
  • Total Institutions
  • Total Govt Holding
  • Total Non Promoter Corporate Holding
  • Total Promoters
  • Total Public & others

About Divi's Laboratories Ltd

Divi's Laboratories Ltd. is one of the leading pharmaceutical companies in the world, manufacturing Active Pharmaceutical Ingredients (APIs), Intermediates and Nutraceuticals. The Company is one of the world's largest API companies, with two manufacturing units and a market presence across 100 countries. It is engaged in the manufacture of Active Pharmaceutical ingredients (API's), Intermediates and Nutraceutical ingredients with predominance in exports. In addition to generic business, the Company, through its custom synthesis business, supports innovator pharma companies for their patented products business right from gram scale requirements for clinical trials to launch as well as late life cycle management. It is among the largest pharmaceutical companies in India with a portfolio of approx. 160 products across diverse therapeutic areas. Presently, it has 6 manufacturing facilities and market presence across several countries. The company has two subsidiaries M/s. Divis Laboratories (USA) Inc., in the United States of America and M/s. Divi's Laboratories Europe AG in Switzerland for marketing its Nutra products and to provide a greater reach to customers within these regions. The company has Research Centers at Sanathnagar, Hyderabad and at the manufacturing sites. Research Centre at Sanathnagar primarily focuses on custom synthesis, contract research for MNC companies as also future generics involving processes like route design, route selection, establishing gram scale process and structural confirmation. Divi's Laboratories Ltd was established in the year 1990 as Divis Research Center (DRC) with Research & Development as their prime fundamental. During the year 1991-93, the company successfully developed several commercial processes for intermediates and bulk actives and supplies to manufacturing majors. In the year 1994, they changed their name to Divis Laboratories Ltd to reflect their growing area of operations. In the year 1995, the company started operations in their manufacturing facility (Unit I) at Choutuppal near Hyderabad. In the year 1997, the company was certified as ISO-9002 compliant by SGS-Yarsley of U.K. In the year 1999, European Directorate gave a 'Certificate of Suitability' (CoS) for Naproxen produced by the company. In the year 2001, the company received OHSAS-18001 Certification from BVQI of London for their Occupational Health and Safety Management Systems. In the year 2002, the company commenced setting up of their second manufacturing facility (Unit II) at Chippada near Visakhapatnam. In the year 2003, they opened a new research center christened 'DRC-Vizag' for fundamental research in selected niche business core segments. The company went for initial public offering (IPO) and their shares were listed on Bombay Stock Exchange and National Stock Exchange. In the year 2004, the company invested an amount of Rs 3035.21 lakh towards capital expenditure at their manufacturing facilities at Choutuppal (Unit-I) and Chippada (Unit-II) for additional machinery installed at both Unit-I and Unit-II. In the year 2006, the company received letter of approval from Ministry of Commerce, Government of India, for setting up a sector-specific special economic zone (SEZ) for pharmaceutical ingredients at Chippada, Bheemunipatnam in Visakhapatnam with investment of Rs 200 crore. The company's second manufacturing site at Chippada, was converted into Export Oriented Unit (EOU) and started operations as EOU from June 1, 2006. During the year 2006-07, the company developed an SEZ titled 'Divi's Pharma SEZ' on a 250-acre site at Chippada, Visakhapatnam. During the year 2007-08, the company set up new production as well as utility facilities in SEZ and EOU Units, and enhanced existing capacities at Unit-1. They commissioned Nutraceuticals Manufacturing facility at Divi's Pharma SEZ and commenced commercial operations effective June 1, 2008. During the year 2008-09, the company added 9 products to their product portfolio of which 4 are generic APIs and intermediates and 5 are custom synthesis APIs and intermediates. During the year 2009-10, they added 7 products to their product portfolio of which 2 are generic APIs and intermediates and 5 are custom synthesis APIs and intermediates. During the year 2010-11, the company added 21 products to their product portfolio of which 8 are generic APIs and intermediates and 13 are custom synthesis APIs and intermediates. The company set up a new facility called 'DSN SEZ Unit' at Chippada in Visakhapatnam at an estimated cost of Rs 200 crore for creating additional capacities for the new opportunities in generic as well as custom synthesis segment. The DSN SEZ Unit commenced commercial operations from June 1, 2011. During the year 2012-13, the company added 9 products to its product portfolio of which 3 are generic APIs and intermediates and 6 are custom synthesis APIs and intermediates. In 2014, the Korean Food and Drug Administration (KFDA) carried out inspection of the company's Visakhapatnam Unit-2 for the third time. During the year, fourth US FDA inspection was carried out at the company's Visakhapatnam Unit-2. Also during the year, fifth US FDA inspection was carried out for Unit-1. During the year, COFEPRIS (Mexico) inspected the company's Visakhapatnam Unit-2 for the first time. COFEPRIS (Mexico) also inspected the company's Choutuppal Unit-1 in Telangana for the first time in the year 2014. On 19 February 2016, Divi's Laboratories announced that it has had a successful inspection by the US-FDA for its Unit-2 at Chippada, Bheemunipatnam near Visakhapatnam during February 2016 with no observations. The Board of Directors of Divi's Laboratories at its meeting held on 12 August 2016 approved and ratified one-time ex-gratia of an aggregate amount of Rs 79 crore to the employees and whole-time directors of the company on the occasion of completion of 25 years of formation of the company. On 8 April 2017, Divi's Laboratories announced that the US-FDA has exempted some more products manufactured at the company's Unit-II at Visakhapatnam from import alert issued under clauses 66-40 and 99-32 of the FDA regulations. On 22 April 2017, Divi's Laboratories announced that the US-FDA has issued a warning letter for the company's Unit-II at Visakhapatnam. On 4 August 2017, Divi's Laboratories announced that the inspection of the Unit-2 Visakhapatnam was completed successfully by HPRA (Ireland) and JAZMP (Slovenia). The inspection was focused on follow up on the effectiveness of the CAPA implemented from the last JAZMP inspection and general GMP inspection of the site. On 15 November 2017, Divi's Laboratories announced that the US-FDA has lifted/removed import alert 66-40 imposed on the company's Unit-II at Visakhapatnam. On 18 November 2017, Divi's Laboratories announced that the company has received an Establishment Inspection Report (EIR) from US-FDA for Unit-II at Visakhapatnam, as closure of audit by FDA. Earlier, the company had informed the stock exchanged that its Unit-II at Visakhapatnam was inspected by US-FDA in September 2017 wherein a Form-483 was issued with 6 observations. On 16 May 2018, Divi's Laboratories announced that its Unit-I at Choutuppal, Telangana has had an inspection by the US-FDA from 14th May 2018 to 16th May, 2018. This was a general cGMP inspection by the FDA. The inspection has been concluded with no 483 observations. As on 31 March 2018, the company has two overseas subsidiaries M/s. Divis Laboratories (USA) Inc., in the United States of America and M/s. Divi's Laboratories Europe AG in Switzerland for marketing its Nutra products. During the year 2017-18, the company is making capacity additions at the existing manufacturing facilities and in this process we are building 2 additional production blocks at Unit-1 at Choutuppal. Capital WIP as at the year-end amounted to Rs 11976 lakhs. Capital expenditure incurred at the existing Units is to enhance capacities as well as upgrading utilities and infrastructure for compliances. As the company has significant accumulation of cash reserves, all capex has been funded with internal accruals. In order to cater to the increasing opportunities in generic and big pharma business, the Company during the FY2019, is taking up following two brownfield projects with an aggregate investment of Rs 1200 crore.a. An SEZ Unit at our Unit-II at Visakhapatnam, named as DCV SEZ Unit, with an investment of Rs 600 crore. (revised from the estimate of Rs 400 crore announced at the last General Meeting),b. Another SEZ Project with an investment of Rs 600 crore in the available land at our Unit-I in Bhuvangiri-Yadadri (erstwhile Nalgonda) District, Telangana State. The Company has commenced commercial operations from a part of the DC-SEZ Unit in February, 2020, and from a part of the DCV-SEZ Unit in March 2020. The Company has also taken up debottlenecking programs at Unit-I as well as Unit-II by investing an aggregate amount of Rs 300 crore -which would also create additional capacities for existing products. In addition, the company also taken up augmentation of waste treatment infrastructure at Unit-II at an estimated cost of Rs 150 crore. A part of the backward integration, debottlenecking and utility expansion projects have come into utilization this year. The rest of these projects will be completed and come into utilization by end of second half of financial year 2020-21. The balance works of the brownfield projects of DC-SEZ and DCVSEZ are also expected to be completed by second half of financial year 2020-21. As on 31 March 2020, the company has two overseas subsidiaries M/s. Divis Laboratories (USA) Inc., in the United States of America and M/s. Divi's Laboratories Europe AG in Switzerland for marketing its Nutra products. Eventhough there was a nationwide lockdown restrictions due to COVID-19 pandemic since March 24, 2020, the Government has exempted manufacturing units of essential goods including drugs and pharmaceuticals, medical devices, their raw materials and intermediates from the lockdown restrictions, amongst others. The Company has been operating in compliance with the various advisories/ guidelines passed by the Government of India, State Governments and statutory institutions. The new brownfield DC and DCV SEZ Units and the debottlenecking / backward integration programs taken up by the company during the last year, have become fully operational during the FY2021. Also Modernization and upgradation of waste water treatment plants at the manufacturing sites has been implemented. During the year 2020-21, the company also taken up another capex program with an estimated investment of Rs 400 crore for fast-tracking a customs synthesis project. During the year 2022, company has taken up several capacity expansion programs at the Company's manufacturing facilities besides plant upgradation, augmenting the utility and support infrastructure.

Divi's Laboratories Ltd Chairman Speech

I would like to thank everyone at Divi’s for their unwavering commitment in response to Covid-19 pandemic and serve our customers through these challenging times. The resilience of our business model will enable us to emerge stronger and ensure reliability in an ever-changing dynamic world.

Dear Shareholders,

The financial year 2021-22 began on a subdued note owing to repeated attacks of the pandemic, taking a severe toll on lives and economies. As the world navigated through the pandemic, the escalation of geopolitical strife compounded the crisis and brought numerous other challenges in the form of strained geopolitical and trade relations, a runaway inflation and unprecedented volatility in commodity costs.

In the face of such flux, the industry showed resilience and adaptability, ensuring continuous supply of medicines to help patients gain access to their medication.

The pandemic has accelerated significant change in the healthcare ecosystem, making it more adaptable and innovative in order to withstand unexpected challenges and capitalise on the opportunities.

In this uncertain operating environment, our focus remained on the health and safety of our people, ensuring uninterrupted supply of our products to meet the evolving demand of our customers and our business needs. This has strongly positioned us as a reliable supplier to the global pharmaceutical companies.

The year in review

The year had been challenging with several headwinds and against this backdrop, our results for the year demonstrate our execution prowess, agility, strategic clarity and the strength of supply chain.

Our core investment for the past two years on debottlenecking, capacity expansion and backward integration strength helped us achieve scale and de-risk external starting material dependence. Our agile business model and stable supply chain ensured minimal business disruption and uninterrupted supply to our customers across the globe.

The commitment and determined efforts of the entire Divi’s family helped us live up to the name of a reliable supplier of API’s.

As a global leader of API’s, we have always accommodated the sudden increase in market demands quickly. We have also sucessfully completed the capacity expansions that we have taken up during the year.

Keeping our Green commitment

During the year FY2022, apart from creating additional capacities for our pipeline products and new capacities for emerging custom synthesis projects, we have also upgraded our utility infrastructure, which also includes environment management.

We strive to create brand value by adopting sustainable practices and implementing Green chemistry principles.

As an industry leader and a responsible enterprise, we served the communities around our manufacturing facilities in several ways by enhancing the village infrastructure, providing safe drinking water, empowering women and improving public healthcare.

Future focused – Agile, consistent and reliable

As we enter a new financial year, we are better prepared to handle the evolving demand, continuous market volatility and an uncertain economic environment.

At Divi’s, we aim to exceed the internal benchmark so that we can consistently deliver value to our customers, and also perform as a dependable supplier.

Our focus will remain on Continuous process innovation and Green chemistry implementation to further establish Divi's as a strong sustainable organisation and deliver value added performance.

I would like to take this opportunity and thank our employees for their consistent effort to deliver the best results despite the challenges. I thank all the stakeholders for reposing their trust in us, which has made Divi’s a reliable brand.

We will continue to strive for leadership through chemistry and be the most reliable supplier of high-quality API’s while creating value for all our stake holders.

Dr. Murali K. Divi

Managing Director

   

Divi's Laboratories Ltd Company History

Divi's Laboratories Ltd. is one of the leading pharmaceutical companies in the world, manufacturing Active Pharmaceutical Ingredients (APIs), Intermediates and Nutraceuticals. The Company is one of the world's largest API companies, with two manufacturing units and a market presence across 100 countries. It is engaged in the manufacture of Active Pharmaceutical ingredients (API's), Intermediates and Nutraceutical ingredients with predominance in exports. In addition to generic business, the Company, through its custom synthesis business, supports innovator pharma companies for their patented products business right from gram scale requirements for clinical trials to launch as well as late life cycle management. It is among the largest pharmaceutical companies in India with a portfolio of approx. 160 products across diverse therapeutic areas. Presently, it has 6 manufacturing facilities and market presence across several countries. The company has two subsidiaries M/s. Divis Laboratories (USA) Inc., in the United States of America and M/s. Divi's Laboratories Europe AG in Switzerland for marketing its Nutra products and to provide a greater reach to customers within these regions. The company has Research Centers at Sanathnagar, Hyderabad and at the manufacturing sites. Research Centre at Sanathnagar primarily focuses on custom synthesis, contract research for MNC companies as also future generics involving processes like route design, route selection, establishing gram scale process and structural confirmation. Divi's Laboratories Ltd was established in the year 1990 as Divis Research Center (DRC) with Research & Development as their prime fundamental. During the year 1991-93, the company successfully developed several commercial processes for intermediates and bulk actives and supplies to manufacturing majors. In the year 1994, they changed their name to Divis Laboratories Ltd to reflect their growing area of operations. In the year 1995, the company started operations in their manufacturing facility (Unit I) at Choutuppal near Hyderabad. In the year 1997, the company was certified as ISO-9002 compliant by SGS-Yarsley of U.K. In the year 1999, European Directorate gave a 'Certificate of Suitability' (CoS) for Naproxen produced by the company. In the year 2001, the company received OHSAS-18001 Certification from BVQI of London for their Occupational Health and Safety Management Systems. In the year 2002, the company commenced setting up of their second manufacturing facility (Unit II) at Chippada near Visakhapatnam. In the year 2003, they opened a new research center christened 'DRC-Vizag' for fundamental research in selected niche business core segments. The company went for initial public offering (IPO) and their shares were listed on Bombay Stock Exchange and National Stock Exchange. In the year 2004, the company invested an amount of Rs 3035.21 lakh towards capital expenditure at their manufacturing facilities at Choutuppal (Unit-I) and Chippada (Unit-II) for additional machinery installed at both Unit-I and Unit-II. In the year 2006, the company received letter of approval from Ministry of Commerce, Government of India, for setting up a sector-specific special economic zone (SEZ) for pharmaceutical ingredients at Chippada, Bheemunipatnam in Visakhapatnam with investment of Rs 200 crore. The company's second manufacturing site at Chippada, was converted into Export Oriented Unit (EOU) and started operations as EOU from June 1, 2006. During the year 2006-07, the company developed an SEZ titled 'Divi's Pharma SEZ' on a 250-acre site at Chippada, Visakhapatnam. During the year 2007-08, the company set up new production as well as utility facilities in SEZ and EOU Units, and enhanced existing capacities at Unit-1. They commissioned Nutraceuticals Manufacturing facility at Divi's Pharma SEZ and commenced commercial operations effective June 1, 2008. During the year 2008-09, the company added 9 products to their product portfolio of which 4 are generic APIs and intermediates and 5 are custom synthesis APIs and intermediates. During the year 2009-10, they added 7 products to their product portfolio of which 2 are generic APIs and intermediates and 5 are custom synthesis APIs and intermediates. During the year 2010-11, the company added 21 products to their product portfolio of which 8 are generic APIs and intermediates and 13 are custom synthesis APIs and intermediates. The company set up a new facility called 'DSN SEZ Unit' at Chippada in Visakhapatnam at an estimated cost of Rs 200 crore for creating additional capacities for the new opportunities in generic as well as custom synthesis segment. The DSN SEZ Unit commenced commercial operations from June 1, 2011. During the year 2012-13, the company added 9 products to its product portfolio of which 3 are generic APIs and intermediates and 6 are custom synthesis APIs and intermediates. In 2014, the Korean Food and Drug Administration (KFDA) carried out inspection of the company's Visakhapatnam Unit-2 for the third time. During the year, fourth US FDA inspection was carried out at the company's Visakhapatnam Unit-2. Also during the year, fifth US FDA inspection was carried out for Unit-1. During the year, COFEPRIS (Mexico) inspected the company's Visakhapatnam Unit-2 for the first time. COFEPRIS (Mexico) also inspected the company's Choutuppal Unit-1 in Telangana for the first time in the year 2014. On 19 February 2016, Divi's Laboratories announced that it has had a successful inspection by the US-FDA for its Unit-2 at Chippada, Bheemunipatnam near Visakhapatnam during February 2016 with no observations. The Board of Directors of Divi's Laboratories at its meeting held on 12 August 2016 approved and ratified one-time ex-gratia of an aggregate amount of Rs 79 crore to the employees and whole-time directors of the company on the occasion of completion of 25 years of formation of the company. On 8 April 2017, Divi's Laboratories announced that the US-FDA has exempted some more products manufactured at the company's Unit-II at Visakhapatnam from import alert issued under clauses 66-40 and 99-32 of the FDA regulations. On 22 April 2017, Divi's Laboratories announced that the US-FDA has issued a warning letter for the company's Unit-II at Visakhapatnam. On 4 August 2017, Divi's Laboratories announced that the inspection of the Unit-2 Visakhapatnam was completed successfully by HPRA (Ireland) and JAZMP (Slovenia). The inspection was focused on follow up on the effectiveness of the CAPA implemented from the last JAZMP inspection and general GMP inspection of the site. On 15 November 2017, Divi's Laboratories announced that the US-FDA has lifted/removed import alert 66-40 imposed on the company's Unit-II at Visakhapatnam. On 18 November 2017, Divi's Laboratories announced that the company has received an Establishment Inspection Report (EIR) from US-FDA for Unit-II at Visakhapatnam, as closure of audit by FDA. Earlier, the company had informed the stock exchanged that its Unit-II at Visakhapatnam was inspected by US-FDA in September 2017 wherein a Form-483 was issued with 6 observations. On 16 May 2018, Divi's Laboratories announced that its Unit-I at Choutuppal, Telangana has had an inspection by the US-FDA from 14th May 2018 to 16th May, 2018. This was a general cGMP inspection by the FDA. The inspection has been concluded with no 483 observations. As on 31 March 2018, the company has two overseas subsidiaries M/s. Divis Laboratories (USA) Inc., in the United States of America and M/s. Divi's Laboratories Europe AG in Switzerland for marketing its Nutra products. During the year 2017-18, the company is making capacity additions at the existing manufacturing facilities and in this process we are building 2 additional production blocks at Unit-1 at Choutuppal. Capital WIP as at the year-end amounted to Rs 11976 lakhs. Capital expenditure incurred at the existing Units is to enhance capacities as well as upgrading utilities and infrastructure for compliances. As the company has significant accumulation of cash reserves, all capex has been funded with internal accruals. In order to cater to the increasing opportunities in generic and big pharma business, the Company during the FY2019, is taking up following two brownfield projects with an aggregate investment of Rs 1200 crore.a. An SEZ Unit at our Unit-II at Visakhapatnam, named as DCV SEZ Unit, with an investment of Rs 600 crore. (revised from the estimate of Rs 400 crore announced at the last General Meeting),b. Another SEZ Project with an investment of Rs 600 crore in the available land at our Unit-I in Bhuvangiri-Yadadri (erstwhile Nalgonda) District, Telangana State. The Company has commenced commercial operations from a part of the DC-SEZ Unit in February, 2020, and from a part of the DCV-SEZ Unit in March 2020. The Company has also taken up debottlenecking programs at Unit-I as well as Unit-II by investing an aggregate amount of Rs 300 crore -which would also create additional capacities for existing products. In addition, the company also taken up augmentation of waste treatment infrastructure at Unit-II at an estimated cost of Rs 150 crore. A part of the backward integration, debottlenecking and utility expansion projects have come into utilization this year. The rest of these projects will be completed and come into utilization by end of second half of financial year 2020-21. The balance works of the brownfield projects of DC-SEZ and DCVSEZ are also expected to be completed by second half of financial year 2020-21. As on 31 March 2020, the company has two overseas subsidiaries M/s. Divis Laboratories (USA) Inc., in the United States of America and M/s. Divi's Laboratories Europe AG in Switzerland for marketing its Nutra products. Eventhough there was a nationwide lockdown restrictions due to COVID-19 pandemic since March 24, 2020, the Government has exempted manufacturing units of essential goods including drugs and pharmaceuticals, medical devices, their raw materials and intermediates from the lockdown restrictions, amongst others. The Company has been operating in compliance with the various advisories/ guidelines passed by the Government of India, State Governments and statutory institutions. The new brownfield DC and DCV SEZ Units and the debottlenecking / backward integration programs taken up by the company during the last year, have become fully operational during the FY2021. Also Modernization and upgradation of waste water treatment plants at the manufacturing sites has been implemented. During the year 2020-21, the company also taken up another capex program with an estimated investment of Rs 400 crore for fast-tracking a customs synthesis project. During the year 2022, company has taken up several capacity expansion programs at the Company's manufacturing facilities besides plant upgradation, augmenting the utility and support infrastructure.

Divi's Laboratories Ltd Directors Reports

To

The Members,

Divi’s Laboratories Limited

Your Directors’ have pleasure in presenting the 32nd Annual Report of Divi’s Laboratories Limited ("the Company" or "Divi’s") along with the audited financial statements for the financial year ended March 31, 2022. The consolidated performance of the Company and its subsidiaries ("Group") has been referred to wherever required.

Financial Results

Financial performance of the Company for the year ended March 31, 2022 is summarized below:

Particulars

Standalone

Consolidated

2021-22 2020-21 2021-22 2020-21
Revenue 8,87,982 6,79,861 8,95,983 6,96,940
Other Income 11,126 6,253 11,387 6256
Total Income 8,99,108 6,86,114 9,07,370 7,03,196
Expenditure before depreciation, interest 5,00,336 3,97,793 5,07,789 4,10,946
Profit before depreciation, interest and tax (PBDIT) 3,98,772 2,88,321 399,581 2,92,250
Depreciation 31,055 25,465 31,151 25,559
Finance Cost 65 69 80 87
Profit before Tax (PBT) 3,67,652 2,62,787 3,68,350 2,66,604
Tax Expense:
Current Tax 63,720 60,905 64,400 61,646
Deferred Tax 9,078 6,410 7,905 6,529
Total Tax 72,798 67,315 72,305 68,175
Profit after Tax (PAT) 2,94,854 1,95,472 2,96,045 1,98,429
Other comprehensive Income (net of tax) 218 16 406 40
Total Comprehensive Income 2,95,072 1,95,488 2,96,451 1,98,469
Earnings per Share of H 2/- each (EPS) Basic & Diluted 111.07 73.63 111.52 74.75

Operations

Standalone

We have been able to achieve yet another year of decent business growth and profitability. The company has been able to conduct its operations with agility and resilience, duly handling the unprecedented covid pandemic and simultaneously quickly responded to the emerging opportunities.

During the year, the fast-track project taken up for an MNC customer was fully operational and achieved significant business. With our dynamic business model supported by our multi-purpose manufacturing facilities, we have been able to cater to customer demands and ensure speed of delivery.

Some of the highlights of the operations for the year are:

• Revenue for the year increased by 31% to H 8,87,982 lakhs.

• Profit before Tax (PBT) for the year has grown by 40% to H 3,67,652 lakhs.

• Tax Provision for the current year amounted to H 72,798 lakhs as against a tax provision of H 67,315 lakhs for the last year.

• Profit after Tax (PAT) for the year grew by 51% to H 2,94,854 lakhs as against a PAT of H 1,95,472 lakhs last year.

• Earnings Per Share of H 2/- each works out to H 111.07 for the year as against H 73.63 last year.

• Out of the total revenue, North America accounted for 44% and Europe for 33%.

Consolidated

The Group’s total consolidated income increased by 29% to H 9,07,370 lakhs from H7,03,196 lakhs in the previous year.

Profit before tax (PBT) for the year grew by 38% to H 3,68,350 lakhs as against H 2,66,604 lakhs in the previous year. Profit after Tax for the year has increased by 49% to H 2,96,045 lakhs as against H 1,98,429 lakhs in the previous year.

Subsidiaries

The Company has 2 wholly owned subsidiaries viz., M/s. Divis Laboratories (USA) Inc., in USA and M/s. Divi’s Laboratories Europe AG in Switzerland, which are engaged in marketing/ distribution of nutraceutical products and to provide a greater reach to customers within these regions.

During the year, the subsidiaries have achieved revenue of H 48,845 lakhs as against H 45,631 lakhs in the previous year, reflecting a growth of 7% of revenue at the subsidiary level.

Subsidiaries are successful in establishing their market presence and in achieving consistent revenue. There has been no material change in the nature of the business of the subsidiaries.

As per Section 129(3) of the Companies Act, 2013 read with Companies (Accounts) Rules, 2014, statement containing the salient features of the financial statement of Company’s subsidiaries in form AOC-1 is annexed herewith as "Annexure I". Moreover, pursuant to provisions of Section 136(1) of the Companies Act, 2013, audited financial statements of the subsidiary companies are placed on the Company’s website and can be accessed at (https://www.divislabs.com/Subsidiary-Financials-2022.pdf.) The Consolidated Financial Statements presented by the Company include the financial results of its subsidiary companies.

Policy for determining Material Subsidiaries, is available on the Company’s corporate website and can be accessed at: (https:// www.divislabs.com/MaterialSubsidiaryPolicy.pdf.) Presently, the Company does not have any material subsidiary.

Consolidated financial statements

As stipulated in the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations") and the Companies Act, 2013 ("the Act"), the consolidated financial statements have been prepared by the Company in accordance with the relevant accounting standards. The audited consolidated financial statements together with Auditor’s Report thereon form part of the Annual Report.

Capital Expenditure

During the year, the Company has capitalized Property, Plant and Equipment (PPE) and Intangible Assets valuing H 93,456 lakhs. Capital Work-in-Progress (WIP) as at the year-end amounted to H 46,993 lakhs.

During the year, the company has taken up several capacity expansion programs at the Company’s manufacturing facilities besides plant upgradation, augmenting the utility and support infrastructure.

Material Changes and Commitments

No other material changes and commitments have occurred after the close of the financial year till the date of this Report, which affect the financial position of the Company. Further, there is no change in the nature of business of the Company.

Dividend

Your Directors are pleased to recommend a dividend of H 30/- per equity share of H 2/- each, i.e., 1500% for the financial year ended March 31, 2022, subject to approval of members at the ensuing Annual General Meeting. The Dividend, if approved, will be paid to shareholders whose names appear in the Register of Members as on the book closure / record date.

The total dividend payout for the current year amounts to H 79,641 lakhs as against H 53,094 lakhs in the previous year. Dividend payout as a percentage of profits is 27% in line with the previous year. Payment of dividend to members will be subject to tax deduction at source (TDS) as per statutory requirement.

ThedividendrecommendedisinaccordancewiththeCompany’s Dividend Distribution Policy. The Dividend Distribution Policy is available on the Company’s website and can be accessed at (https://www.divislabs.com/DividendDistributionPolicy.pdf.)

Transfer to Reserves

The Directors have decided to retain the entire total comprehensive income for the current year in Other Equity.

Deposits

The Company has not accepted any deposits from public covered by provisions of Section 73 of the Act.

Loans, Guarantees or Investments

The Company has not given any loans or guarantees covered under the provisions of Section 186 of the Act. The details of investments made by the Company are given in the notes to the financial statements forming part of this annual report.

Related Party Transactions

There are no materially significant related party transactions made by the Company with related parties which may have potential conflict of interest with the Company at large. As a matter of policy, your Company carries out transactions with related parties on an arms’ length basis. Statement of these transactions is given at Note No. 37 of the Notes to financial statements.

Accordingly, particulars of contracts or arrangements with related parties referred to in Section 188(1) of the Act along with the justification for entering into such contract or arrangement in prescribed Form AOC-2 does not form part of this report.

The Policy on Materiality of Related Party Transactions and on dealing with Related Party Transactions as approved by the Board is available on the Company’s website and can be accessed at (https://www.divislabs.com/RPT-Policy.pdf.)

Internal Financial Controls

Information in respect of internal financial controls and their adequacy is included in the Management Discussion and Analysis, which forms part of this Annual report.

Risk Management

The Company has a Risk Management Committee of the Board. The brief of terms of reference, composition and names of members and chairperson are set out in the Corporate Governance Report forming part of the Report.

The Company has an enterprise-wide approach to risk management, which lays emphasis on identifying and managing key operational and strategic risks. The aim is to avoid or minimise risks that pose a threat to Divi’s continued existence and to make improved managerial decisions to create value. The Company has been addressing various risks impacting the Company pursuant to the Risk Management Policy.

The Risk Management Committee constantly evaluates various risks – business, customer concentration, supplier concentration, regulatory compliances, confidentiality of processes, consistency of cGMP practices, environment, employee health and safety etc., monitors risks and deploy appropriate control systems aimed at mitigating such risks to the extent possible. The Audit Committee reviews the risk elements of the company’s business, finance, operations and compliance, and their respective mitigation strategies.

Further details on the Risk Management activities including key risks identified, and their mitigations are covered in Management Discussion and Analysis Report, forming part of this Annual Report.

During the financial year 2021-22, the focus areas of Risk Management Committee included review of cyber security and data protection, business continuity, various ESG risks.

Management Discussion and Analysis

In terms of provisions of Regulation 34(2) of SEBI Listing Regulations report on Management Discussion & Analysis for the year under review is provided in a separate section forming part of this Annual Report.

Directors’ Responsibility Statement

As required under Section 134 (5) of the Act, Directors of your Company hereby state and confirm that:

a) the applicable accounting standards read with requirements of Schedule III to the Act have been followed in the preparation of the annual accounts for the year ended March 31, 2022 and there are no material departures from the same;

b) accounting policies selected were applied consistently and the judgements and estimates made are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company as at the end of the financial year and of the profit of the Company for the period;

c) proper and sufficient care has been taken for the maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;

d) the annual accounts have been prepared on a going concern basis.

e) internal financial controls have been laid down and such controls are adequate and operating effectively;

f) proper systems have been laid down to ensure compliance with the provisions of all applicable laws and such systems are adequate and operating effectively.

Number of Meetings of Board of Directors

The Board meets at least four times in a year at quarterly intervals and more frequently if deemed necessary, to transact its business. During the financial year, the Board has met four times, i.e. May 29, 2021, August 07, 2021, November 06, 2021 and February 11, 2022.

Directors and Key Managerial Personnel

During the financial year, the Members of the Company have approved re-appointment of Dr. Ramesh B.V. Nimmagadda as an Independent Director for a second term of 5 years effective from June 27, 2022, including approval pursuant to Regulation 17(1A) of the SEBI Listing Regulations for his continuation as Independent Director upon attaining 75 years of age on August 14, 2022. The Members also approved re-appointment of Dr. Ganapaty Seru as an Independent Director for a second term of 5 years effective from July 22, 2022.

Further, the Members have re-appointed Ms. Nilima Prasad Divi as Whole-time Director (Commercial) of the Company for a further period of 5 years with effect from June 27, 2022 and approved her remuneration.

Mr. N.V. Ramana and Mr. Madhusudana Rao Divi retires by rotation at the forthcoming 32nd AGM and being eligible, offer themselves for re-appointment.

Declaration by Independent Directors

The Company received declaration from all the Independent Directors of the Company under Section 149(7) of the Act and Regulation 25 of the SEBI Listing Regulations, confirming that they meet the criteria of independence as provided in Section 149(6) of the Act and Regulation 16(1)(b) of SEBI Listing Regulations and there has been no change in the circumstances affecting their status as Independent Directors of the Company. Further, they have confirmed compliance to the code of conduct for independent directors as prescribed in Schedule IV of the Act. In the opinion of the Board, the Independent Directors of the Company possess necessary expertise, integrity and experience.

Performance Evaluation

The Board of Directors carried out an annual evaluation of its own performance, of the Committees of the Board and of the individual directors including Independent Directors, pursuant to the provisions of the Companies Act, 2013 and SEBI Listing Regulations.

Performance evaluation was carried out on the basis of criteria evolved, as provided by the Guidance Note on Board Evaluation issued by Securities and Exchange Board of India, seeking inputs from the Directors individually and the committees through a structured questionnaire which provides a valuable feedback for contribution to the Board, improving Board effectiveness, maximising strengths and highlighting areas for further improvement, etc.

In a separate meeting of the Independent Directors, performance of the Chairperson, non-independent directors and the Board as a whole was evaluated taking into account the views of the non-independent directors and the same was discussed in the Board Meeting. Performance evaluation of Independent Directors is done by the entire Board of Directors (excluding the Directors being evaluated).

The details of the Separate meeting of the Independent Directors are reported in the Report on Corporate Governance which forms part of the Board’s Report.

Policy on Directors’ Appointment and Remuneration

The Policy on appointment and remuneration of directors, key managerial persons (KMP) and senior management including criteria for determining qualifications, positive attributes and director’s independence as required under Section 178(3) of the Act, and Regulation 19 read with Schedule II Part D of SEBI Listing Regulations has been formulated by the Company, inter-alia includes:

• To identify persons who are qualified to become directors and who may be appointed in senior management in accordance with the criteria laid down.

• To ensure a transparent board nomination process with the diversity of thought, experience, knowledge, perspective and gender in the Board.

• To determine remuneration based on the Company’s size and financial position and trends and practices on remuneration prevailing in peer companies, in the Pharma industry besides qualifications, skills, capabilities, etc.

• To carry out evaluation of the performance of Directors, as well as Key Managerial and Senior Management Personnel.

• To provide them rewards linked directly to their effort, performance, dedication and achievement relating to the Company’s operations.

• To retain, motivate and promote talent and to ensure long term sustainability of talented managerial persons and create competitive advantage.

Policy on Nomination and Remuneration of Directors, Key / Senior Managerial Personnel may be accessed on the Company’s website at: https://www.divislabs.com/ NominationRemunerationPolicy.pdf.

Remuneration details of Directors & KMP

Pursuant to Section 197(12) of the Act, read with Rule 5(1) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, the prescribed particulars pertaining to remuneration and other details are given in "Annexure – II" to this Report.

The non-executive directors of the Company had no pecuniary relationship or transactions with the Company, other than sitting fees, annual remuneration and reimbursement of expenses, if any.

During the year, Dr. Kiran S. Divi received H 40 lakhs remuneration from the Company’s wholly owned subsidiary, Divi’s Laboratories Europe AG, for the services rendered by him in the capacity of Director. Pursuant to the terms of appointment of Dr. Kiran S. Divi to the extent of the remuneration paid at subsidiary is reduced from his salary payable by Divi’s Laboratories Limited.

Particulars of Employees

Particulars of employees required to be furnished under Rule 5(2) and 5(3) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, as amended are given in "Annexure – III" and forms part of this Report.

Corporate Social Responsibility

The Board of Directors has constituted Corporate Social Responsibility Committee (CSR Committee) consisting of members viz. Mr. R. Ranga Rao (Chairman), Dr. Murali K. Divi, Mr. Madhusudana Rao Divi and Dr. Ramesh B.V. Nimmagadda.

Corporate Social Responsibility Policy (CSR Policy) indicating the activities to be undertaken by the Company was adopted by the Board on the recommendation of the CSR Committee.

Report on Corporate Social Responsibility as per Rule 8 of Companies (Corporate Social Responsibility Policy) Rules, 2014 is prepared and the same is enclosed as "Annexure – IV" to this Report.

Business Responsibility Report

Pursuant to the SEBI Listing Regulations, Business Responsibility Report (BRR) describing the initiatives taken by the Company is enclosed as part of this Report.

Conservation of Energy, Technology Absorption and Foreign Exchange Earnings & Outgo

Particulars required under Section 134 (3) (m) of the Act read with Rule 8(3) of the Companies (Accounts) Rules, 2014 is given in the "Annexure – V" to this report.

Corporate Governance Report

The report on Corporate Governance as per Regulation 34(3) read with Schedule V of the SEBI Listing Regulations is included as a part of this Annual Report. The requisite certificate from Mr. V. Bhaskara Rao, Practicing Company Secretary confirming the compliance with the conditions of Corporate Governance is attached to the report on Corporate Governance.

Audit Committee

The details pertaining to the role, objective and composition of the Audit Committee are included in the Corporate Governance Report forming part of this Annual Report.

Vigil Mechanism

The Company has established a vigil mechanism and formulated a Whistle Blower Policy to provide mechanism for directors and employees of the Company to report their concerns about any unethical behavior, actual or suspected fraud or violation of the Company’s code of conduct or ethics policy. The Policy provides that the Company investigates such incidents, when reported, in an impartial manner and takes appropriate action to ensure that requisite standards of professional and ethical conduct are always upheld. This mechanism also provides for adequate safeguards against victimization of director(s)/ employee(s) who avail the mechanism and also provide for direct access to the Chairman of the Audit Committee in exceptional cases. The Whistle Blower Policy may be accessed on the Company’s website at: (https:// www.divislabs.com/WhistleBlowerPolicy.pdf.)

Audit Reports

• Report of the Statutory Auditors on the financial statements for the year does not contain any qualification, reservation or adverse remark or disclaimer; or reporting of any offence or fraud.

• The Secretarial Audit Report does not contain any qualification, reservation or adverse remark or disclaimer.

• The Auditors have not reported any instances of frauds to the Audit Committee as prescribed under Section 143(12) of the Act.

Statutory Auditors

M/s. Price Waterhouse Chartered Accountants LLP (Firm Registration No. 012754N/ N500016), chartered accountants, were appointed as statutory auditors of the Company to hold office for five consecutive years from the conclusion of the 27th Annual General Meeting (AGM) of the Company held on September 25, 2017 till the conclusion of the 32nd AGM to be held in the year 2022.

M/s. Price Waterhouse Chartered Accountants LLP will complete their first term of five consecutive years as the statutory auditors of the Company at the conclusion of the 32nd AGM of the Company.

Pursuant to Section 139(2) of the Act, the Company can appoint M/s. Price Waterhouse Chartered Accountants LLP for a second term of five consecutive years.

The Audit Committee and the Board of Directors recommend to the Members for the reappointment of M/s. Price Waterhouse Chartered Accountants LLP, as statutory auditors of the Company for a second term of five consecutive years from the conclusion of the 32nd AGM till the conclusion of 37th AGM to be held in the year 2027.

M/s. Price Waterhouse Chartered Accountants LLP have consented to the said reappointment, and confirmed that their reappointment, if made, would be within the limits specified under Section 141(3)(g) of the Act. They have further confirmed that they are not disqualified to be reappointed as statutory auditor in terms of the provisions of the Act, and the provisions of the Companies (Audit and Auditors) Rules, 2014, as amended from time to time.

Secretarial Audit

Pursuant to provisions of Section 204 of the Act and the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, the Board of Directors of the Company has appointed Mr. V. Bhaskara Rao, Practicing Company Secretary (PCS Registration No. 4182) as the Secretarial Auditor of the Company to conduct the Secretarial audit for the financial year 2021-22. The Secretarial Audit report for the financial year 2021-22 is annexed herewith as "Annexure - VI".

Cost Audit

Pursuant to the Section 148 of the Act and Rule 3 of the Companies (Cost Records and Audit) Rules, 2014 as amended, the Company maintains cost records in its books of account. As per Rule 4 of the said rules, the requirement for cost audit is not applicable to a company which is covered under Rule 3, and whose revenue from exports, in foreign exchange, exceeds seventy five per cent of its total revenue or which is operating from a special economic zone. However, the Company has voluntarily opted for audit of cost records and appointed M/s. E.V.S & Associates, Cost Accountants as Cost Auditors.

Annual Return

In terms of Section 92(3) of the Act and Rule 12 of the Companies (Management and Administration) Rules, 2014, the Annual Return of the Company as on March 31, 2022 is available on the Company’s website and can be accessed at (https://www. divislabs.com/annual-return/2021-22.pdf)

Other Disclosures

• Information on Unclaimed Dividend and transfer to IEPF is provided in the Corporate Governance Report.

• No Company has become or ceased to be its subsidiary, joint venture or associate company during the year.

• No significant and material orders were passed by the regulators or courts or tribunals impacting the going concern status and Company’s operations in future.

• The Company has complied with provisions relating to the constitution of Internal Complaints Committee under the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013 and rules made thereunder and during the year under review, there were no complaints received or pending.

• The information with respect to Compensation, Nomination and Remuneration Committee, Stakeholders Relationship Committee, Risk management Committee are disclosed in the Corporate Governance Report forming part of the Annual Report.

• The Company has followed the applicable Secretarial Standards, i.e. SS-1 and SS-2, relating to ‘Meetings of the Board of Directors’ and ‘General Meetings’ respectively.

Acknowledgements

Your Directors take this opportunity to thank the customers, shareholders, suppliers, bankers, business associates, financial institutions and Central and State Governments for their consistent support and encouragement to the Company.

We are sure you will join our Directors in conveying our sincere appreciation to employees at all levels of the Company and its subsidiaries, for their hard work, dedication and commitment, in particular during this unprecedented year, thereby ensuring uninterrupted supply of life saving medicines across the globe.

For and on behalf of the Board
Dr. Ramesh B.V. Nimmagadda Dr. Murali K. Divi
Chairman Managing Director
Place: Hyderabad DIN: 07854042 DIN: 00005040
Date: May 23, 2022

   

Divi's Laboratories Ltd Company Background

Ramesh B V NimmagaddaMurali K Divi
Incorporation Year1990
Registered Office1-72-23(P)/DIVIS/303 Divi Towe,Cyber Hills Gachibowli
Hyderabad,Telangana-500032
Telephone91-40-23786300/23786352/400,Managing Director
Fax91-40-23786460
Company SecretarySatish Choudhury
AuditorPrice Waterhouse Chartered Accountants LLP
Face Value2
Market Lot1
ListingBSE,MSEI ,NSE,
RegistrarKFin Techologies Ltd
Karvy Selenium Tow-B,31&32 Financial Dist,Nanakramguda ,Hyderabad-500032

Divi's Laboratories Ltd Company Management

Director NameDirector DesignationYear
Murali K Divi Chairman & Managing Director 2022
N V Ramana Executive Director 2022
Madhusudana Rao Divi Whole Time Director (Projects) 2022
Kiran S Divi Whole Time Director & CEO 2022
G Suresh Kumar Independent Director 2022
Ranga Rao Ravipati Independent Director 2022
K V K Seshavataram Independent Director 2022
Ramesh B V Nimmagadda Chairman(Non Exe)&Director(Ind 2022
Nilima Motaparti Whole Time Director -Commercia 2022
S Ganapaty Independent Director 2022
Sunaina Singh Independent Director 2022
Kosaraju Veerayya Chowdary Independent Director 2022
Satish Choudhury Company Secretary 2022

Divi's Laboratories Ltd Listing Information

Listing Information
NIFTY
BSE_500
BSE_HC
BSE_100
BSE_200
BSEDOLLEX
CNX500
CNXPHARMA
CNX100
CNX200
BSEGREENEX
BSECARBONE
NFT100EQWT
BSEALLCAP
BSELARGECA
BSEMANUFAC
NFTQULTY30
SENSEX50
LMI250
BSEDSI
NFT50EQWT
BSE100LTMC
NFTYLM250
NFTY200Q30
NFTYHEALTH
NF500M5025

Divi's Laboratories Ltd Finished Product

Product NameUnit Installed
Capacity
Production
Quantity
Sales
Quantity
Sales
Value
Sale of ProductsNA0008708.1
Sale of ScrapNA000106.95
Export incentivesNA00053.65
Sale of ServicesNA00011.12
API IntermediatesMT0000
API Intermediates TradedNA0000
Bulk Drugs & Interm.-OthersMT0000
Traded GoodsNA0000
Excise DutyNA0000
Other Operating RevenueNA0000

Contact us Contact us